135936-08-2

Basic information

• Product Name: 1-Amino-2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butane
• Synonyms: 1-Amino-2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butane
• CAS NO: 135936-08-2
• Molecular Weight: 318.243
• Mol File: 135936-08-2.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: 1-Amino-2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Amino-2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butane(135936-08-2)
• EPA Substance Registry System: 1-Amino-2-(3,4-dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butane(135936-08-2)

Safety Data

• Hazardous Substances Data: 135936-08-2(Hazardous Substances Data)

Upstream product

• 135936-16-2 α-[2-(Tetrahydropyran-2-yloxy)ethyl]-3,4-dichlorophenyl-acetonitrile 
• 1336-21-6 ammonium hydroxide 
• 142-68-7 TETRAHYDROPYRANE 
• 152298-51-6 2-(2-Hydroxyethyl)-2-(3,4-dichlorobenzene)ethanamine 
• 17739-45-6 2-(2-bromoethoxy)tetrahydropyran 
• 110-87-2 3,4-dihydro-2H-pyran 

Downstream Products

• 152298-51-6 2-(2-Hydroxyethyl)-2-(3,4-dichlorobenzene)ethanamine 
• 159874-12-1 N-[2-(3,4-Dichlorophenyl)-4-(tetrahydropyran-2-yloxy)butyl]-benzamide 
• 1489051-39-9 β-Hydroxyethyl-3,4-dichlorobenzeneethanamine 

Relevant articles and documents

CARBOXY SUBSTITUTED CARBOXAMIDE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS

-

Carboxy substituted acylic carboxamide derivatives

The present invention relates to novel carboxy substituted acyclic carboxamide derivatives of formula (1)): STR1and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis.

SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) {1,4}DIAZEPAN-1-YL)-2-(ARYL)BUTYL) BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES

The present invention relates to novel N-methyl-N-(4-(4-(1H-benzimidazol-2-yl)[1,4]diazepan-1-yl)-2-(aryl)butyl)benzamide derivatives of the formula: STR1 stereoisomers thereof, and pharmaceutically acceptable salts thereof which are useful as histamine receptor antagonists and tachykinin receptor antagonists. Such antagonists are useful in the treatment of allergic rhinitis, including seasonal rhinitis and sinusitis; inflammatory bowel diseases, including Crohn's disease and ulcerative colitis; asthma; bronchitis; and emesis.